Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Lecturer who called Israel a terrorist state to remain Plaid Cymru candidate - 2UN chief warns he could refer Israel to ICJ over laws targetting UNRWA
- 3Colleges say foreign students feel 'unwelcome' in the U.S. amid big drop in international enrollment, new survey finds
- 4New findings suggest atmosphere could exist on exoplanet TOI-561b
- 5Activists Took BMW and Mercedes to Court Over Gas Cars. It Didn’t Stick
- Father and son spending Christmas together after health scares
- Baby takes 1st steps after receiving groundbreaking gene-edited therapy
- What's inside Mexico's Popocatépetl? Scientists obtain first 3D images of the whole volcano
- A 'Stranger Things' documentary covering the final season is on its way: Watch the trailer
- France bans Muslim gathering citing risk to participants
- Eat Well, Live Well: An Extensive Manual for Smart dieting and Sustenance
- 10 Distinct Kinds of Chinese Neighborhood Specialty Hot Pot
- The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices
- Reclassifying Achievement: Individual Accounts of Seeking after Interests
